Novo Nordisk Korea will lose about 100 billion to 175 billion won of Wegovy revenue over the next 12 months.

Hanmi's Eppe won approval on 7 October as Korea's first homegrown GLP-1 obesity drug and is due on sale by year end. Patients pay the full cost themselves. A rival priced at least 30% below Wegovy forces a direct comparison. Wegovy is the weaker import because it holds about 15% of injectable sales against Eli Lily’s Mounjaro's 78%. Novo already cut Wegovy's starting dose by up to 42% before Mounjaro launched. It is likely to cut again and lose market share to Hanmi. The projected loss is four to seven times Novo Korea's 2025 operating profit of 24.2 billion won – while Lilly keeps its premium position.